Barclays maintains Overweight on McKesson, cuts target to $925

0 min read | Published on 10 Jun 2026, 08:52 PM |Updated on 10 Jun 2026, 08:52 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

Barclays analyst Glen Santangelo maintains an Overweight rating on McKesson but lowers the price target to $925 from $1050, reflecting a revised valuation outlook.

*this image is generated using AI for illustrative purposes only.

Barclays analyst Glen Santangelo has maintained an Overweight rating on McKesson while lowering the price target to $925 from $1050. The revised target suggests a shift in the stock's valuation expectations despite the positive rating.

Rating and Price Target Details

The decision to retain the Overweight rating indicates continued confidence in McKesson's performance relative to its sector. However, the reduction in the price target highlights a recalibration of the stock's potential upside.

Metric	Value
Rating	Overweight
Previous Price Target	$1050
New Price Target	$925

The adjustment comes as analysts reassess market conditions and company-specific factors influencing McKesson's future earnings trajectory.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific market conditions or company-specific factors led to the recalibration of McKesson's valuation?

How might this price target reduction influence investor sentiment towards McKesson in the short term?

What are the potential risks to McKesson's earnings trajectory that could further impact its stock performance?

McKesson stock returns 15.03% annually over 20 years

0 min read | Published on 09 Jun 2026, 03:12 AM |Updated on 09 Jun 2026, 03:12 AM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

McKesson delivered an average annual return of 15.03% over the last 20 years, outpacing the market by 5.79% annually. With a current market cap of $92.15 billion, a $100 investment made two decades ago would now be worth $1,681.60.

*this image is generated using AI for illustrative purposes only.

McKesson has generated an average annual return of 15.03% over the past 20 years, outperforming the market by 5.79% on an annualized basis. This performance highlights the impact of compounded returns on long-term capital growth. The company currently commands a market capitalization of $92.15 billion.

Investment Growth Analysis

The substantial growth in shareholder value is illustrated by the performance of a hypothetical investment. If an investor had purchased $100 worth of McKesson stock 20 years ago, that holding would be valued significantly higher today.

Investment Horizon	Initial Investment	Current Value	Current Share Price
20 Years	$100	$1,681.60	$766.64

The data underscores the financial benefits of long-term investment strategies in equities that demonstrate consistent performance. The current valuation reflects the cumulative effect of the company's annualized returns over the specified period.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What factors could drive McKesson's continued outperformance in the evolving healthcare sector?

How might changes in healthcare policy impact McKesson's future growth trajectory?

Is McKesson's current valuation sustainable given its historical performance?